News

Alofanib Preclinical Research Study

Publication [Download PDF]: Tyulyandina, A., Harrison, D., Yin, W. et al. Invest New Drugs (2017) 35: 127. https://doi.org/10.1007/s10637-016-0404-1

Ovarian cancer is notorious for its poor prognosis; five-year survival rates for are 40% and 18% for stages III and IV, respectively. Ovarian cancer classifications are defined by the origin cell types and include papillary serous histology, mucinous, endometroid, clear cell, transitional cell and undifferentiated subtypes. Surgical resection and chemotherapy are standard ovarian cancer treatments. First line chemotherapy is typically a combination of paclitaxel and carboplatin and has remained the same for over 15 years. While initial response rates are approximately 80%, recurrent disease is fatal in most patients. Tyulyandina et al. (Investigational New Drugs, 2017) presented preclinical data for alofanib (RPT835), a novel small-molecule allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2) with antitumor activity against ovarian cancer in combination with platinum based cytotoxic agents.

FGFR2 is upstream of the MAPK, AKT1 and RAS signaling pathways. Its abnormal upreguation via either amplification or high-level polysomy is correlated to advanced serous ovarian cancer. In order to investigate the effects of alofanib in ovarian cancer, a series of in vitro and in vivo experiments were performed using SKOV3 cancer cells with the help of Altogen Laboratories. SKOV3 cell lysates were analyzed via automated western blotting (Wes) for FGFR1-3 protein levels; it was found that FGFR1 and FGFR2 but not FGFR3 were expressed. SKOV3 cells were confirmed to demonstrate a basic FGF-mediated increase in proliferation which was inhibited by alofanib at a GI50 value of 0.37 µM/L. SKOV3 xenografts were established in immunocompromised mice and treated daily with a combination of alofanib with paclitaxel/carboplatin. Tumor size, vessel density (CD31) and Ki-67 histological staining results demonstrated an alofanib-mediated inhibition of tumor growth, angiogenesis and cell proliferation. The lack of death and body weight loss in the mice suggests that alofanib does not affect toxicity of the regimen. Overall, this study supports the concept of using FGFR inhibitors to augment traditional ovarian cancer chemotherapy to potentially improve patient outcome and overcome platinum resistance.

Altogen Labs is a contract research organization (CRO) that specializes in preclinical research services for pharmaceutical, academic and biotechnology needs. As with this 2017 alofanib study, examples of such services range from in vitro to in vivo experiments including protein expression analysis, cell proliferation and death assays, histological studies, drug screening, IC50 evaluation, xenograft studies, RNAi targeting and delivery and more with over 100 cell models to choose from. This Austin, TX based company has a dedicated team of experienced scientists to advise, perform and analyze experiments in a Good Laboratory Practice (GLP) setting. Altogen Labs offers instant quotes at competitive pricing and is committed to delivering high quality and efficient results.

Altogen Labs offers in vivo imaging services for drug development and biodistribution studies: Orthotopic glioma xenograft model

Altogen Labs provides in vivo imaging services for drug development and biodistribution studies: U87 orthotopic glioma xenograft animal model study  by Altogen Labs, 11200 Manchaca Rd, Suite 203 Austin TX 78748 USA Download full text PDF:  Introduction In vivo imaging has emerged as a critical tool in visualization in preclinical research studies related to the development… Continue Reading

Xenograft Models for Preclinical Research: From Translational Studies to Clinical Trials

AUSTIN, TX, December 17, 2018 Altogen Labs, a biotechnology laboratory focused on the development of innovative cancer therapeutics, today announced the addition of new CDX models (MDA-MB-157, MDA-MB-453, U87, and OVCAR-3). The addition of these xenograft models further increases Altogen Labs’ product line in breast and ovarian cancer, as well as glioblastoma to 89 CDX,… Continue Reading

Medical Discovery and Innovation: Altogen Labs Preclinical CRO Services

Altogen Labs Preclinical CRO Services Altogen Labs (altogenlabs.com), an Austin, TX based contract research organization (CRO) offers preclinical laboratory services to pharmaceutical, biotechnology, and academic researchers worldwide to support and accelerate medical discovery and research studies. Our Good Laboratory Practice (GLP)-compliant laboratory located at 11200 Manchaca Rd, Suite 203, Austin TX offers services for drug toxicology, drug efficacy, drug… Continue Reading

Altogen Labs Xenograft Services for Drug Development Studies of Anticancer Therapeutics

Altogen Labs announced addition of five new in-house validated xenograft models (4T1, BxPC-3, Calu-6, MDA-MB-468, and PANC-1). This will make a total of 89 CDX xenograft models and 29 PDX xenograft models provided by Altogen Labs. Murine models have been used to investigate human cancer, enabling the discovery and development of new anticancer medicines. Xenograft… Continue Reading

Altogen Labs offers xenograft services for drug development of anti-cancer therapeutics

Altogen Labs provides xenograft services for drug development studies of anti-cancer therapeutics by Altogen Labs, Preclinical CRO, 11200 Manchaca Rd, Suite 203 Austin TX 78744 USA (512-433-6177) Contact e-mail: info@altogenlabs.com Introduction Xenograft studies fuels the development of new therapeutics efficiently and effectively and remains the gold standard for preclinical oncology research [1]. Xenograft studies, over… Continue Reading

Preclinical Contract Research Studies by Global Health & Pharma

Altogen Labs is a good laboratory practice (GLP) compliant laboratory that provides biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide. Altogen Labs services include safety in vivo toxicology studies (for IND applications), efficacy studies (for regulatory submissions), drug discovery (patent applications), drug development and other types of R&D studies – pharm/tox, bio distribution and imaging studies. Altogen Labs was established in 2009 in Austin,… Continue Reading

Biology CRO Contract Research Services to Accelerate Preclinical and Oncology Research Studies

Altogen Labs, a CRO laboratory located in Austin, Texas (USA), provides preclinical pharmacology and oncology contract research services for pharmaceutical, biotechnology, and academic research institutions worldwide. Company scientists bring years of experience and expertise in life science and drug discovery research services. Altogen Labs offers GLP-compliant research and development services that include preclinical trials to… Continue Reading

Altogen Labs Offers Pre-Clinical CRO Services to Accelerate Pre-Clinical Research Needs

Altogen Labs, a biotechnology company focused on providing biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide, announced pre-clinical contract research services enabling companies to accelerate pre-clinical research needs. Pre-clinical trials assess the toxicity and pharmacological activity of investigative new drugs (INDs) to assess a compound’s therapeutic potential and safety for human use. A… Continue Reading